Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development of therapies for the treatment of central and peripheral nervous system, and pain in Italy and the United States. The company offers Xadago (safinamide) for the treatment of Parkinson's disease, as well as develops Xadago for the treatment of levodopa induced dyskinesia. It also develops Evenamide for Schizophrenia and treatment resistant schizophrenia; and Ralfinamide for orphan indication in neuropathic pain. Newron Pharmaceuticals S.p.A. was founded in 1999 and is headquartered in Bresso, Italy.

Newron Pharmaceuticals S.p.A.

Newron Pharmaceuticals is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. The company has built a late-stage pipeline that includes one marketed product and product candidates in clinical development.

msh id	COM:NEWRON
symbol	NWRN
name	Newron Pharmaceuticals S.p.A.
homepage url	https://www.newron.com
country	IT
sector	-
industry	-
market	STOCKS
employee count	23
crunchbase url	-
linkedin url	-
founders	-

market cap	157.57M
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	0.05
growth cost of revenue	-
growth depreciation and amortization	4.43
growth ebitda	0.11
growth ebitda ratio	0.4
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-0.44
growth gross profit	0.49
growth gross profit ratio	-

COM:NEWRON

Newron Pharmaceuticals

Last Close

7.28

22/11 12:12

Market Cap

136.34M

Beta: -

Volume Today

20.22K

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	22.33M
cost of revenue	22.33M
depreciation and amortization	217.01K
ebitda	-12.77M
ebitda ratio	-1.31
eps	-0.98
eps diluted	-0.98
operating expenses	22.33M
operating income	-12.56M
operating income ratio	-1.28

accounts receivables	-
capital expenditure	-11.88K
cash at beginning of period	14.49M
cash at end of period	6.84M
inventory	-
working capital ttm	23.45M

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-